Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030


Player Tracking System Market Growth & Trends

The global player tracking system market size is estimated to reach USD 20.44 billion by 2030, expanding at a CAGR of 20.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The continued emphasis of the coaching staff of prominent teams on tracking and enhancing the performance of players is expected to drive the growth of the market. Efforts aimed at preventing injuries to players are also necessitating the use of an appropriate player tracking system, thereby contributing to the growth of the market.

GPS-based tracking systems are expected to witness a high rate of adoption over the forecast period. The ease of installation, affordability, and availability are increasingly encouraging various sports teams to utilize GPS-based tracking systems for practice sessions as well as during tournaments. Many colleges and universities have started using GPS trackers for their football and rugby teams owing to similar reasons. For instance, Baylor University from Texas, University of Oregon, University of North Carolina, and Vanderbilt University from Nashville are some of the educational institutes in the U.S. that are using GPS trackers to monitor the performance of their players.

Asia Pacific is emerging as one of the promising regional markets for player tracking system companies. Several sports leagues in the region are increasingly adopting different kinds of tracking systems for players. For instance, the Board of Control for Cricket in India (BCCI) had signed a deal with STATSport Group, asports tech company based in the U.K., to implement a GPS-based player tracking system for the Indian cricket team ahead of the ICC Cricket World Cup 2019 to measure physical metrics of individual players.

However, the market is getting highly competitive as new entrants are foraying into the market with innovative and customized products. For instance, Gpexe System and Catapult Sports have launched wireless charging GPS trackers for players. These devices can be paired with smartphones to track the players in real time using dedicated apps. Moreover, market players are also forming strategic alliances with sports teams to gain a competitive advantage in the market. For instance, in March 2019, Sonda Sports announced a collaboration with Lions Rugby Co., a South African rugby team, to provide GPS tracking system. Similarly, in April 2019, Kinexon partnered with Brose Bamberg, a German basketball team from Bamberg, North Bavaria, to provide a sports tracking system.

Player Tracking System Market Report Highlights
  • The services segment is expected to exhibit the highest CAGR over the forecast period owing to the growing demand for application-based monitoring systems.
  • The wearables segment is expected to register a high growth rate owing to the affordability and easy availability of GPS trackers.
  • The team sports segment is expected to exhibit the highest CAGR owing to the continued adoption of latest tracking technologies.
  • The Asia Pacific region is expected to advance at the fastest CAGR from 2025 to 2030 owing to the continued rollout of high-speed internet networks and proliferation of smart devices in the sports industry.
  • Some of the prominent players of player tracking system market include ChyronHego Corporation, Stats LLC, STATSports Group, and SPT Group Pty Ltd., among others.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Disease Stage
1.2.3. Distribution channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug and disease stage outlook
2.2.2. Distribution channel outlook
2.3. Competitive Insights
Chapter 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of Non-Alcoholic Steatohepatitis (NASH) disease
3.2.1.2. Rising awareness about disease
3.2.1.3. Robust product pipeline and rising R&D
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Stringent regulations
3.3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pipeline Analysis
Chapter 4. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Movement Analysis
4.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Drug, Revenue (USD Million)
4.4. Bronchodilators
4.4.1. Vitamin E and Pioglitazone market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Obeticholic Acid (OCA)
4.5.1. Obeticholic Acid (OCA) market estimates and forecasts 2018 - 2030 (USD Million)
4.6. Lanifibranor
4.6.1. Lanifibranor market estimates and forecasts 2018 - 2030 (USD Million)
4.7. Semaglutide
4.7.1. Semaglutide market estimates and forecasts 2018 - 2030 (USD Million)
4.8. Resmetirom
4.8.1. Resmetirom market estimates and forecasts 2018 - 2030 (USD Million)
4.9. Aramchol
4.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
4.10. Aramchol
4.10.1. Aramchol market estimates and forecasts 2018 - 2030 (USD Million)
4.11. Cenicriviroc
4.11.1. Cenicriviroc market estimates and forecasts 2018 - 2030 (USD Million)
4.12. Other Drugs
4.12.1. Other drugs market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Movement Analysis
5.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Disease Stage, Revenue (USD Million)
5.4. NASH Stage F0
5.4.1. NASH stage F0 market estimates and forecasts 2018 - 2030 (USD Million)
5.5. NASH Stage F1
5.5.1. NASH stage F1 market estimates and forecasts 2018 - 2030 (USD Million)
5.6. NASH Stage F2
5.6.1. NASH stage F2 market estimates and forecasts 2018 - 2030 (USD Million)
5.7. NASH Stage F3
5.7.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
5.8. NASH Stage F3
5.8.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Movement Analysis
6.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospitals Pharmacies
6.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Retail and Specialty Pharmacies
6.5.1. Retail and Specialty Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Other Pharmacies
6.6.1. Other pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Estimates & Trend Analysis By Product, Application, and End Use
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.3.2. Intercept Pharmaceuticals, Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Galmed Pharmaceuticals Ltd.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Inventiva.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. AbbVie Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Galectin Therapeutics Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Madrigal Pharmaceuticals Inc (Madrigal).
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. NGM Biopharmaceuticals, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Novo Nordisk A/S
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. The Bristol-Myers Squibb Company
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Gilead Sciences, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings